Breaking News

Moderna Shares Clinical Data on COVID Booster Candidate, mRNA-1273.214

Demonstrates superior antibody response against omicron.

Author Image

By: Charlie Sternberg

Associate Editor

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern.   A 50 µg booster dose of mRNA-1273.214 met all pre-specified endpoints including superior neutralizing antibody response (geometric mean ratio) against the Omicron variant one month after adminis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters